The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA

Virology

Volumn 310, Issue 2, 2003, Pages 333-342

  Zhou, Sifang ^a,b   Liu, Rong ^a   Baroudy, Bahige M ^a   Malcolm, Bruce A ^a   Reyes, Gregory R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BioReliance Corporation   (United States)

Author keywords

Combination therapy; Hepatitis C virus; Inosine 5 monophosphate dehydrogenase inhibitor; Mutagenesis; Replicon; Ribavirin

Indexed keywords

GENOMIC RNA; GUANOSINE; INOSINATE DEHYDROGENASE INHIBITOR; MERIMEPODIB; MYCOPHENOLIC ACID; RIBAVIRIN; ANTIMETABOLITE; CARBAMIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; ENZYME INHIBITOR; INOSINATE DEHYDROGENASE; N 3 (3 (3 METHOXY 4 OXAZOL 5 YLPHENYL)UREIDO)BENZYLCARBAMIC ACID TETRAHYDROFURAN 3 YL ESTER; N-3-(3-(3-METHOXY-4-OXAZOL-5-YLPHENYL)UREIDO)BENZYLCARBAMIC ACID TETRAHYDROFURAN-3-YL ESTER; RNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; GENE SEQUENCE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REPLICON; RNA ISOLATION; BIOSYNTHESIS; CELL LINE; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; MUTATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS GENOME; VIRUS REPLICATION;

HEPATITIS C VIRUS; POLIOVIRUS;

ANTIMETABOLITES; CARBAMATES; CELL LINE, TRANSFORMED; ENZYME INHIBITORS; GENOME, VIRAL; GUANOSINE; HEPACIVIRUS; HUMANS; IMP DEHYDROGENASE; MUTATION; MYCOPHENOLIC ACID; PHENYLUREA COMPOUNDS; REPLICON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA; RNA, VIRAL; TRANSFECTION; VIRUS REPLICATION;

EID: 85047692907     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00152-1     Document Type: Article

References (43)

1. Alter, H.J.. Seeff, L.B., 2000. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20. 17 35.
2. Blight, K.J, Kolykhalov, A.A., Rice, CM., 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972-1974.
3. Bodenheimer, H.C.J., Lindsay, K.L., Davis, G.L., Lewis, J.H., Thung, S.N., Seeff. L.B., 1997. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 26, 473-477.
4. Cameron, C.E., Castro, C.. 2001. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA dependent RNA polymerase. Curt. Opin. lnfect. Dis. 14, 757-764.
5. Carr, S.F., Papp, E., Wu, J.C., Natsumeda, Y., 1993. Characterization of human type I and type lI IMP dehydrogenases. J. Biol. Chem. 268, 27286-27290.
6. Cassidy, L.F., Patterson, J.L., 1989. Mechanism of La Crosse virus inhibition by ribavirin.. Antimicrob. Agents Chemother 33, 2009-2011.
7. Chung, R.T., He, W., Saquib, A., Contreras, A.M., Xavier, R.J., Chawla, A., Wang, T.C., Schmidt, E.V., 2001. Hepatitis C virus replication is directly inhibited by 1FN-alpha in a full-length binary expression system. Proc. Natl. Acad. Sci. USA 98, 9847-9852.
8. Contreras, A.M., Hiasa, Y., He, W., Terella, A., Schmidt, E.V., Chung, R.T., 2002. Viral RNA mutations are region specific and increased by ribavifin in a full-length hepatitis C virus replication system. J. Virol. 76, 8505-8517.
9. Crotty, S., Cameron, C.E., Andino, R., 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA 98, 6895-6900.
10. Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., Andino, R., Cameron, C.E., 2000. The broad-spectrum antiviral fibonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6, 1375-1379.
11. Davis, G.L., Esteban-Mur, R., Rustgi, V., Hoers, J., Gordon, S.C., Trepo, C., Shiffman, M.L., Zeuzem, S., Craxi, A., Ling, M.H., Albrecht, J., 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1493-1499.
12. De Clercq, E., Cools, M., Balzarini, J., Snoeck, R., Andrei, G., Hosoya, M., Shigeta, S., Ueda, T., Minakawa, N., Matsuda, A., 1991. Antiviral activities of 5-ethynyl-1-beta-D-ribofumnosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35, 679-684.
13. Domingo, E., 2000. Viruses at the edge of adaptation. Virology 270, 251-253.
14. Dusheiko, G., Main, J., Thomas, H., et al., 1996. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J. Hepatol. 25,591-598.
15. Eigen, M., 1971. Selforganization of maner and the evolution of biological macromolecules. Naturwissenschaften 58, 465-523.
16. Eriksson, B., Helgstrand, E., Johansson, N.G.L, arsson, A., Misiorny, A., Noren, J.O., Philipson, L., Stenberg, K., Stening, G., Stridh, S., Oberg, B., 1977. Inhibition of influenza virus ribonucleic acid polymerase by ribavifin triphosphate. Antimicrob. Agents Chemother. 11,946-951.
17. Fried, M.W., Shiffman, M.L., Reddy, K.R., et al., 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982.
18. Glue, P., 1999. The clinical pharmacology of ribavirin. Semin. Liver Dis. 19 (Suppl. 1), 17-24.
19. Grande-Perez, A., Sierra, S., Castro, M.G., Domingo, E., Lowenstein, P.R., 2002. From the cover: molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. USA 99, 12938-12943.
20. Holland, J.J., Domingo, E., de la Torre, J.C., Steinhauer, D.A., 1990. Mutation frequencies al defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol. 64, 3960-3962.
21. Khakoo, S., Glue, P., Grellier, L., Wells, B., Bell, A., Dash, C., MurrayLyon, I., Lypnyj, D., Flannery, B., Walters, K., Dusheiko, G.M., 1998. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br. J. Clin. Pharmacol. 46. 563-570
22. Krieger, N., Lohmann, V, Bartenschlager, R., 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75, 4614-4624.
23. Lanford, R.E., Chavez, D, Guerra, B.. Lau, J.Y.N., Hong, Z., Brasky, K.M., Beames, B., 2001. Ribavirin induces error prone replication of GBV-B in primary tamarin hepatocytes. J. Virol. 75, 8074-8081.
24. Lanford, R.E., Guerra, B., Lee, H., Averett, D.R., Pfeiffer, B., Chavez, D., Notvall, L., Bigger, C., 2003. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(1)-poly(C), tumor necrosis factor alpha, and ribavifin in hepatitis C virus subgenomic replicons. J. Virol. 77, 1092-1104.
25. Lauer, G.M., Walker, B.D., 2001. Hepatitis C virus infection. N. Engl. J. Med. 345, 41-52.
26. Loeb, L.A., Essigrnann, J.M., Kazazi, F., Zhang, J., Rose, K.D., Mullins, J.I., 1999. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. USA 96, 1492-1497.
27. Lohmann, V., Komer, F., Koch, J., Herian, U., Theilmann, L., Barrenschlager, R., 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113.
28. Maag, D., Castro, C., Hong, Z., Cameron, C.E., 2001. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276, 46094-46098.
29. Malinowski, F., Stollar, V., 1981. lnhibitors of IMP dehydrogenase prevent Sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 110, 281-291.
30. Markland, W., McQuaid, T.J., Jain, J., Kwong, A.D., 2000. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 44, 859-866.
31. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht, J.K., 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis lnterventional Therapy Group. N. Engl. J. Med. 339, 1485-1492.
32. Pariente, N., Sierra, S., Lowenstein, P.R., Domingo, E., 2001. Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J. Virol. 75, 9723-9730.
33. Pietschmann, T., Lohmann, V., Rutter, G., Kurpanek, K., Bartenschlager, R., 2001. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75, 1252-1264.
34. Preston, S.L., Drusano, G.L., Glue, P., Nash, J., Gupta, S.K., McNamara, P., 1999. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob. Agents Chemother. 43, 2451-2456.
35. Rankin, J.T.J., Eppes, S.B., Antezak, J.B., Joklik, W.K., 1989. Studies on the tnechanism of the antiviral activity of ribavirin against reovirus. Virology 168, 147-158.
36. Reyes, G.R., 2001. Ribavirin: recent insights into antiviral mechanisms of action. Curt. Opin. Drug Discov. Dev. 4, 651-656.
37. Sidwell, R.W., Huffman, J.H., Khare, G.P., Allen, L.B., Witkowski, J.T., Robins, R.K., 1972. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-l,2,4-triazole-3-carboxamide. Science 177, 705-706.
38. Sierra, S., Davila, M., Lowenstein, P.R.. Domingo, E., 2000. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J. Virol. 74, 8316-8323.
39. Streeter, D.G., Witkowski, J.T., Khare. G.P., Sidwelk R.W., Bauer, R.J., Robins, R.K., Simon, L.N., 1973. Mechanisms of action of 1-β-D- ribofuranosyl-l,2,4-triazole-3-carboxamide (virazole) a new broad spectrum antiviral agent. Proc. Nail Acad. Sci. USA 70, 1174-1178.
40. Tam, R.C., Lau, J.Y.N., Hong, Z., 2001 Mechanisms of action of ribavirin in antiviral therapies. Antimicrob. Agents Chemother. 12, 261-272.
41. Toltzis, P., O'Connell, K.. Patterson, J.L., 1988. Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob. Agents Chemother. 32,492-297.
42. Wasley, A., Alter, M.J., 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20, 1-16.
43. Wray, S.K., Gilbert, B.E., Noall, M.W.. Knight, V., 1985. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Amiviral Res. 5, 29-37.